Abstract:8557 Background: Blood-based methods using circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) are under development for early and less invasive detection of lung cancer, although detection of the earliest stage cancers (stages 0-II) using these modalities is suboptimal. We hypothesized that a machine learning approach using RNA gene expression may offer important information on the biology of the patient, allowing for gene expression profiles to be used as a surrogate measurement of cancer disease phenotype and as a promising direction for early detection of lung cancer. In a previous study, 23 miRNA biomarkers were successfully discovered and validated for the non-invasive diagnostic classification of lung adenocarcinoma, achieving 97.7% sensitivity, 98.7% specificity in blood obtained from 383 clinical subjects. The aim of this study was to train a machine learning algorithm, from the 23 miRNA features, to test the signature for early lung cancer detection. Methods: A large and diverse clinical cohort was obtained from the NIH Gene Expression Omnibus database, GEO Accession Number GSE137140 ( n=3,744), comprised of miRNA extracted from serum samples consisting of subjects with pre-operative lung cancer ( n=1,566) and non-cancer controls ( n=2,178). Our analytic plan leveraged machine learning methods derived from XGBoost classification, a popular supervised-learning algorithm that uses sequentially built shallow decision trees to provide accurate results and avoidance of overfitting. The algorithm was trained using XGBoost 1.4.1.1 R library programmed with R v3.6.3. Results: The lung cancer cohort was heavily weighted towards early-stage lung cancer (87.7% stage I/II), including representation across prevalent histologic types (adenocarcinoma 77.8%, non-adenocarcinoma 22.2%) and those who self-reported as never smokers (37.9%). The 23-miRNA signature achieved 98% sensitivity, 89% specificity in the held-out test set (Table). When incorporating age and gender, the 23-miRNA signature achieved 95.5% sensitivity, 90.3% specificity. Conclusions: A machine learning approach using RNA gene expression in patient serum achieved high sensitivity and specificity in a large, predominantly early-stage, lung cancer cohort. A multi-analyte, multimodal approach that leverages machine learning algorithms with RNA gene expression profiles and available demographics and clinical risk-factors, represents the possibility to accurately detect lung cancer in the earliest stages. This approach has successfully been translated from microarray to PCR instrumentation, with further validation of this machine learning method and approach currently underway. [Table: see text]

Evaluation of Circulating Mirnas for Earlier Cancer Detection Through Machine-Learning Expression Profiling.

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and Mirnas

Exosomal Let-7D-3p and Mir-30D-5p As Diagnostic Biomarkers for Non-Invasive Screening of Cervical Cancer and Its Precursors

Circulating Plasma Mirnas As Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling

A Plasma Mirna-Based Classifier for Small Cell Lung Cancer Diagnosis

Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data.

Development of a novel blood-based RNA gene expression platform for early-stage lung cancer diagnosis.

Constructing a machine learning-based non-invasive liquid biopsy model for lung cancer detection via miRNA sequencing.

Pan-cancer characterization of cell-free immune-related miRNA identified as a robust biomarker for cancer diagnosis

Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer

Proposing new early detection indicators for pancreatic cancer: Combining machine learning and neural networks for serum miRNAbased diagnostic model

miRNA in Machine-Learning-Based Diagnostics of Oral Cancer

Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches

Noninvasive multi-cancer detection using blood-based cell-free microRNAs

MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances

A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer

Expression Profile Of Circulating Micrornas As A Promising Fingerprint For Cervical Cancer Diagnosis And Monitoringy

Microfluidics for Profiling miRNA Biomarker Panels in AI-Assisted Cancer Diagnosis and Prognosis

Computational Analysis of Specific MicroRNA Biomarkers for Noninvasive Early Cancer Detection.

Screening Model for Bladder Cancer Early Detection With Serum miRNAs Based on Machine Learning: A Mixed‐Cohort Study Based on 16,189 Participants